Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets (Current Period Unaudited)

v3.21.2
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2021
Jun. 30, 2021
Current assets:    
Cash and cash equivalents $ 196,321 $ 199,091
Short-term available-for-sale investments 38,740 32,463
Accounts receivable, less allowance for doubtful accounts of $1,273 and $1,229, respectively 147,548 145,385
Inventories 117,366 116,748
Other current assets 43,773 16,919
Total current assets 543,748 510,606
Property and equipment, net 207,134 207,907
Right of use asset 71,396 [1] 73,834
Goodwill 840,020 843,067
Intangible assets, net 596,300 615,968
Other assets 11,589 11,575
Total assets 2,270,187 2,262,957
Current liabilities:    
Trade accounts payable 25,621 29,384
Salaries, wages and related accruals 32,213 51,294
Accrued expenses 17,419 15,282
Contract liabilities 19,121 18,995
Income taxes payable 6,505 5,336
Operating lease liabilities - current 12,001 [1] 11,602
Contingent consideration payable 5,000 4,000
Current portion of long-term debt obligations 12,500 12,500
Other current liabilities 3,612 3,891
Total current liabilities 133,992 152,284
Deferred income taxes 98,812 93,125
Long-term debt obligations 287,723 328,827
Long-term contingent consideration payable 17,600 25,400
Operating lease liabilities 65,059 [1] 67,625
Other long-term liabilities 20,046 24,462
Bio-Techne's Shareholders' equity:    
Undesignated capital stock, no par; authorized 5,000,000 shares; none issued or outstanding 0 0
Common stock, par value $.01 per share; authorized 100,000,000; issued and outstanding 39,273,057 and 38,955,484, respectively 393 390
Additional paid-in capital 583,851 534,411
Retained earnings 1,119,337 1,085,461
Accumulated other comprehensive loss (64,216) (57,291)
Total Bio-Techne's shareholders' equity 1,639,365 1,562,971
Noncontrolling interest 7,590 8,263
Total shareholder's equity 1,646,955 1,571,234
Total liabilities and shareholders’ equity $ 2,270,187 $ 2,262,957
[1] The right of use asset, current operating lease liabilities, and noncurrent lease liabilities on the Consolidated Balance Sheet exclude a definitive agreement entered into by the Company in June 2021 for a 25,000 square foot facility in Dublin, Ireland for the next 25 years with annual rental impact of $0.3 million. The lease will commence during fiscal 2022 after construction is completed by the landlord. As the lease has not commenced as of June 30, 2021, the related asset and liability were not recorded.